Myeloproliferative Neoplasms Clinical Trial

Asciminib Monotherapy, With Dose Escalation, for 2nd Line Chronic Myelogenous Leukemia

Summary

This study will be a single arm multicenter Phase II open-label, dose escalation study of asciminib in patients with leukemia-cml/" >CML-CP without T315I mutation who have had 1 prior TKIs for which they did not respond to treatment or were intolerant to treatment.

View Full Description

Full Description

This trial consists of three periods: screening and baseline for up to 28 days, active treatment for up to 104 weeks and a safety follow up period for 30 days.

Ninety-two (92) patients with chronic myeloid leukemia in chronic phase (CML-CP) without T315I mutation who have had 1 prior Tyrosine Kinase Inhibitors (TKIs) will be considered for the current study.

Informed consent will be obtained before any procedures are performed for the study including eligibility assessments.

Patients with CML-CP without T315I mutation will be enrolled in the single-arm, open label study. For the first 6 months of the treatment period,80 mg asciminib will be taken orally once a day. At six months, patients who have achieved Major Molecular Response (MMR, BCR-ABL1IS <1%) will continue on the 80 mg once a day dosage. For those who did not achieve MMR, patients will increase dosage to 200 mg once a day. At the 12 month or 52 week mark, patients will either continue on 80 mg once a day, 200 mg once a day, or increase to 200 mg twice a day dependent on MMR. Investigators also have the choice to choose the patients dosage at 12 months.

The patients will be treated up to end of study treatment period defined as up to 104 weeks after the last patient receives the first dose. Patients may be discontinued from treatment with the study drug at any time due to unacceptable toxicity, disease progression and/or at the discretion of the investigator or the patient.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Signed informed consent must be obtained prior to participation in the study 2. Chronic Myelogenous Leukemia (CML-CP,) no previous Accelerated Phase (AP) or Blast Crisis (BC) 3. ≥ 18 years of age 4. For CML-CP patients with treatment failure/resistance to first line (1L) Tyrosine Kinase Inhibitor (TKI,) BCR-ABL1IS at screening:

>10% if 1L treatment duration between 6 and 12 months
>1% if 1L treatment longer than 12 months 5. For CML-CP patients with treatment intolerance to 1L TKI, BCR-ABL1IS > 0.1% at screening 6. Previously treated with 1 Adenosine triphosphate- (ATP)-binding site TKI for at least 6 months of therapy 7. Intolerance of TKI therapy and/or resistance to TKI therapy (European Leukemia Network (ELN) 2020)

Intolerance is defined as:

Non-hematologic intolerance: Patients with grade 3 or 4 toxicity while on therapy, or with persistent grade 2 toxicity, unresponsive to optimal management, including dose adjustments (unless dose reduction is not considered in the best interest of the patient if response is already suboptimal)
Hematologic intolerance: Patients with grade 3 or 4 toxicity (absolute neutrophil count [ANC] or platelets) while on therapy that is recurrent after dose reduction to the lowest doses recommended by manufacturer

Resistance/Failure is defined for CML-CP patients (CP at the time of initiation of last therapy) as follows . Patients must meet at least 1 of the following criteria:

Three months after the initiation of therapy: No Complete Hematological Response (CHR) or > 95% Philadelphia Chromosome Positive (Ph+) metaphases
Six months after the initiation of therapy: BCR-ABL1 ratio > 10% IS and/or >65% Ph+ metaphases
Twelve months after initiation of therapy: BCR-ABL1 ratio > 1% IS and/or >35% Ph+ metaphases
At any time after the initiation of therapy, loss of CHR, Complete Cytogenetic Response (CCyR) or Partial Cytogenetic Response (PCyR)
At any time after the initiation of therapy, the development of new BCR-ABL1 mutations which potentially cause resistance to study treatment
At any time after the initiation of therapy, confirmed loss of Major Molecular Response (MMR) in 2 consecutive tests, of which one must have a BCR-ABL1 ratio ≥ 1% IS
At any time after the initiation of therapy, new clonal chromosome abnormalities in Ph+ cells: CCA/Ph+ 8. Adequate end organ function within 12 days before the first dose of asciminib treatment. Patients with mild to moderate renal and hepatic impairment are eligible if:
Total bilirubin ≤ 3.0 x ULN without AST/ALT increase
Aspartate transaminase (AST) ≤ 5.0 x ULN
Alanine transaminase (ALT) ≤ 5.0 x ULN
Serum lipase ≤ 1.5 x ULN. For serum lipase > ULN and ≤ 1.5 x ULN, value should be considered not clinically significant and not associated with risk factors for acute pancreatitis
Alkaline phosphatase ≤ 2.5 x ULN
Creatinine clearance ≥ 30 mL/min as calculated using Cockcroft-Gault formula

Exclusion Criteria:

1. Previous treatment with 2 or more ATP-binding site TKIs 2. Previous treatment with asciminib 3. Known presence of the T315I mutation at any time prior to study entry 4. Known second chronic phase of CML after previous progression to AP/BC 5. Previous treatment with a hematopoietic stem-cell transplantation 6. Patient planning to undergo allogeneic hematopoietic stem cell transplantation 7. Cardiac or cardiac repolarization abnormality, including any of the following:

History within 6 months prior to starting study treatment of myocardial infarction (MI), angina pectoris, coronary artery bypass graft (CABG)
Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia), complete left bundle branch block, high-grade AV block (e.g., bifascicular block, Mobitz type II and third-degree AV block)
QTcF at screening ≥450 msec (male patients), ≥460 msec (female patients)
Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome, or any of the following:
Risk factors for Torsades de Pointes (TdP) including uncorrected hypokalemia or hypomagnesemia, history of cardiac failure, or history of clinically significant/symptomatic bradycardia
Concomitant medication(s) with a "Known risk of Torsades de Pointes" per www.crediblemeds.org that cannot be discontinued or replaced 7 days prior to starting study drug by safe alternative medication.
Inability to determine the QTcF interval 8. History of acute pancreatitis within 1 year of study entry or past medical history of chronic pancreatitis 9. Participation in a prior investigational study within 30 days prior to randomization or within 5 half-lives of the investigational product, whichever is longer 10. Treatment with medications that meet one of the following criteria is not allowed and should be switched to an alternative at least one week prior to the start of treatment with study treatment:
Strong inducers of CYP3A for patients on the dose of 80 mg QD and 200mg QD
Strong inducers and inhibitors of CYP3A for patients on the dose of 200 mg BID 11. Pregnant or nursing (lactating) women 12. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception.
Highly effective contraception methods include:
Total abstinence (when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
Female sterilization (have had surgical bilateral oophorectomy (with or without hysterectomy) total hysterectomy or bilateral tubal ligation at least six weeks before taking study treatment). In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment
Male sterilization (at least 6 months prior to screening). The vasectomized male partner should be the sole partner for that subject
Use of oral, injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS) or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception
In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment
Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or bilateral tubal ligation at least six weeks before taking study medication. In the case of oophorectomy alone, women are considered post-menopausal and not of child-bearing potential only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.

Highly effective contraception for women should be maintained throughout the study and for at least 7 days after the last dose.

13. Sexually active males unwilling to use a condom during intercourse while taking study treatment and for 7 days after stopping study (only for patients treated with asciminib). A condom is required for all sexually active male participants on asciminib treatment to prevent them from fathering a child AND to prevent delivery of study treatment via seminal fluid to their partner. In addition, these male participants must not donate sperm for the time period specified above.

Study is for people with:

Myeloproliferative Neoplasms

Phase:

Phase 2

Estimated Enrollment:

92

Study ID:

NCT05384587

Recruitment Status:

Recruiting

Sponsor:

Novartis Pharmaceuticals

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 26 Locations for this study

See Locations Near You

University of Alabama at Birmingham
Birmingham Alabama, 35233, United States More Info
Omer Jamy
Principal Investigator
City of Hope National Medical Center
Duarte California, 91010, United States More Info
Paul Koller
Principal Investigator
Lundquist Inst BioMed at Harbor
Torrance California, 90509, United States More Info
Saraj Tomassetti
Principal Investigator
Rocky Mountain Cancer Centers USOR
Boulder Colorado, 80304, United States More Info
Contact
303-385-2000
David J Andorsky
Principal Investigator
Emory University School of Medicine/Winship Cancer Institute
Atlanta Georgia, 30308, United States More Info
Contact
404-686-2505
Anthony Michael Hunter
Principal Investigator
Augusta University Georgia Cancer Center Pharmacy
Augusta Georgia, 30912, United States More Info
Contact
404-778-1900
Jorge Cortes
Principal Investigator
Northwest Georgia Oncology Center
Marietta Georgia, 30060, United States More Info
Contact
770-281-5124
Steven McCune
Principal Investigator
University of Chicago Hospital
Chicago Illinois, 60637, United States More Info
Contact
773-702-2084
Richard A Larson
Principal Investigator
University of Kentucky
Lexington Kentucky, 40536, United States More Info
Contact
859-218-5151
Reinhold Munker
Principal Investigator
LSU Health Sciences Center COMB157G2301
Shreveport Louisiana, 71130, United States More Info
Contact
318-813-1452
Poornima Ramadas
Principal Investigator
Dana Farber Cancer Center
Boston Massachusetts, 02215, United States More Info
Marlise Luskin
Principal Investigator
Dartmouth Hitchcock Medical Center
Lebanon New Hampshire, 03756, United States More Info
Contact
603-650-6228
Swaroopa Yerrabothala
Principal Investigator
Hackensack University Medical Center
Hackensack New Jersey, 07601, United States More Info
Contact
201-996-5900
James Mcclowsky
Principal Investigator
Manhattan Hematol Oncol Associates
New York New York, 10016, United States More Info
Alec Goldenberg
Principal Investigator
SUNY Upstate Medical Center
Syracuse New York, 13210, United States More Info
Contact
315-464-4353
Krishna Ghimire
Principal Investigator
Novant Health Heart and Vascular Institute
Charlotte North Carolina, 28204, United States More Info
James Dugan
Principal Investigator
Duke University Medical Center
Durham North Carolina, 27710, United States More Info
Lindsay Rein
Principal Investigator
Wake Forest University Health Sciences Oncology
Winston-Salem North Carolina, 27157, United States More Info
Contact
336-716-7972
Bayard L. Powell
Principal Investigator
Hematology Oncology Care
Cincinnati Ohio, 45236, United States More Info
Contact
513-751-2273
Kruti Patel
Principal Investigator
Oregon Health and Science University
Portland Oregon, 97239, United States More Info
Michael Charles Heinrich
Principal Investigator
Texas Oncology P A TX Oncology Baylor
Dallas Texas, 75251, United States More Info
Moshe Yair Levy
Principal Investigator
University of TX MD Anderson Cancer Center
Houston Texas, 77030, United States More Info
Contact
713-792-2828
Koji Sasaki
Principal Investigator
Utah Cancer Specialists UT Cancer Cnt
Salt Lake City Utah, 84106, United States More Info
S Disean Kendall
Principal Investigator
Huntsman Cancer Institute
Salt Lake City Utah, 84112, United States More Info
Srinivas Tantravahi
Principal Investigator
VA Puget Sound Health Care System
Seattle Washington, 98108, United States More Info
Contact
800-329-8387
Robert Richard
Principal Investigator
Medical College of Wisconsin
Milwaukee Wisconsin, 53226, United States More Info
Contact
414-805-5249
Ehab Atallah
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Myeloproliferative Neoplasms

Phase:

Phase 2

Estimated Enrollment:

92

Study ID:

NCT05384587

Recruitment Status:

Recruiting

Sponsor:


Novartis Pharmaceuticals

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.